Pulmatrix Acquires Eos SENOLYTIX in Definitive Merger

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

April 6, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX Ltd

October 30, 2025

Biotechnology

Swiss-based NLS Pharmaceutics Ltd. merged with clinical-stage cell therapy company Kadimastem Ltd. to create a combined Nasdaq-listed biotechnology company named NewcelX Ltd. The merger closed effective October 30, 2025, with the new company beginning trading on the Nasdaq Capital Market on October 31, 2025 under ticker “NCEL.”

Pulmatrix to Merge with Cullgen to Form Nasdaq-Listed Company Focused on Targeted Protein Degradation

November 13, 2024

Biotechnology

Pulmatrix announced a proposed merger with Cullgen to create a Nasdaq-listed biopharmaceutical company focused on targeted protein degradation, including three degrader programs in or about to begin Phase 1 clinical trials. The combined company is expected to operate as Cullgen Inc. headquartered in San Diego, California, with closing expected by end of March 2025 subject to approvals. As part of the merger agreement, Pulmatrix plans to divest certain assets, and Pulmatrix stockholders are expected to receive a special cash dividend contingent on net cash at closing.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Electromedical Products International Acquires Pulvinar Neuro

March 17, 2022

Medical Devices

Electromedical Products International (EPI) has acquired Pulvinar Neuro, a research-oriented medical device company focused on closed-loop neuromodulation and digital therapeutics. The deal expands EPI's scientific and research capabilities to accelerate development and commercialization of Pulvinar's transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics.